AAG
LUCD icon

Accordant Advisory Group’s Lucid Diagnostics LUCD Stock Holding History

Accordant Advisory Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Hold
14,300
– – 0.01% 154
2026
Q1 		$16.4K Hold
14,300
– – 0.01% 140
2025
Q4 		$15.6K Buy
14,300
+9,800
+218% +$11K 0.01% 124
2025
Q3 		$4.54K Buy
+4,500
New +$4.91K ﹤0.01% 146

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Accordant Advisory Group's LUCD Position: Q2 2026 in Review

Accordant Advisory Group held its Lucid Diagnostics (LUCD) position steady in Q2 2026 at 14,300 shares worth $15.3K. The position accounts for 0.01% of the portfolio, ranked #154.

Accordant Advisory Group first reported a position in LUCD in Q3 2025 and has held it in 4 quarters since. The position peaked at $16.4K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Accordant Advisory Group held 14,300 shares of Lucid Diagnostics worth $15.3K as of Q2 2026.
  • Accordant Advisory Group left its Lucid Diagnostics share count unchanged in Q2 2026.
  • Lucid Diagnostics made up 0.01% of Accordant Advisory Group's portfolio in Q2 2026, its #154 holding.
  • Accordant Advisory Group first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 4 quarters since.
  • Accordant Advisory Group's Lucid Diagnostics position peaked at $16.4K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Accordant Advisory Group's 13F filing for Q2 2026, filed 27 Jul 2026.